How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes

被引:31
作者
Boeni-Schnetzler, Marianne
Donath, Marc Y.
机构
[1] Univ Basel Hosp, Clin Endocrinol Diabet & Metab, CH-204031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Biomed, CH-204031 Basel, Switzerland
关键词
cytokines; IL-1; type; 2; diabetes; inflammation; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ISLET-ASSOCIATED MACROPHAGES; BETA-CELL; INSULIN-RESISTANCE; NLRP3; INFLAMMASOME; ACTIVATION; IL-1-BETA; SECRETION; OBESITY; HYPERGLYCEMIA;
D O I
10.1111/j.1365-2125.2012.04297.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolic diseases are associated with activation of the innate immune system in various tissues and characterized by elevated inflammatory factors and the presence of immune cells. Type 2 diabetes develops when islet beta cells are deficient in producing sufficient insulin to overcome peripheral insulin resistance. Intra-islet IL-1 activity diminishes beta cell function and survival and governs islet inflammation. Targeting the IL-1 system with the IL-1 receptor antagonist IL1Ra improved insulin secretion, glycaemia and reduced systemic inflammation in a proof of concept study with patients with type 2 diabetes. Currently, long lasting and specific IL-1 blocking antibodies are being evaluated in clinical trials and this may lead to a novel cytokine-based treatment for type 2 diabetes.
引用
收藏
页码:263 / 268
页数:6
相关论文
共 47 条
[1]   Interleukin-1 receptor antagonist: Role in biology [J].
Arend, WP ;
Malyak, M ;
Guthridge, CJ ;
Gabay, C .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :27-55
[2]   Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance? [J].
Boeni-Schnetzler, Marianne ;
Donath, Marc Y. .
CELL RESEARCH, 2011, 21 (07) :995-997
[3]   Free Fatty Acids Induce a Proinflammatory Response in Islets via the Abundantly Expressed Interleukin-1 Receptor I [J].
Boeni-Schnetzler, Marianne ;
Boller, Simone ;
Debray, Sarah ;
Bouzakri, Karim ;
Meier, Daniel T. ;
Prazak, Richard ;
Kerr-Conte, Julie ;
Pattou, Francois ;
Ehses, Jan A. ;
Schuit, Frans C. ;
Donath, Marc Y. .
ENDOCRINOLOGY, 2009, 150 (12) :5218-5229
[4]   Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation [J].
Boni-Schnetzler, Marianne ;
Thorne, Jeffrey ;
Parnaud, Geraldine ;
Marselli, Lorella ;
Ehses, Jan A. ;
Kerr-Conte, Julie ;
Pattou, Francois ;
Halban, Philippe A. ;
Weir, Gordon C. ;
Donath, Marc Y. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :4065-4074
[5]   Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes Whitehall II Prospective Cohort Study [J].
Carstensen, Maren ;
Herder, Christian ;
Kivimaeki, Mika ;
Jokela, Markus ;
Roden, Michael ;
Shipley, Martin J. ;
Witte, Daniel R. ;
Brunner, Eric J. ;
Tabak, Adam G. .
DIABETES, 2010, 59 (05) :1222-1227
[6]  
Cavelti-Weder C, DIABETES CA IN PRESS
[7]   Interleukin-1β and signaling of interleukin-1 in vascular wail and circulating cells modulates the extent of neointima formation in mice [J].
Chamberlain, J ;
Evans, D ;
King, A ;
Dewberry, R ;
Dower, S ;
Crossman, D ;
Francis, S .
AMERICAN JOURNAL OF PATHOLOGY, 2006, 168 (04) :1396-1403
[8]   Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model - Pharmacotherapeutic implications [J].
Chi, HH ;
Messas, E ;
Levine, RA ;
Graves, DT ;
Amar, S .
CIRCULATION, 2004, 110 (12) :1678-1685
[9]   Interleukin-1 in the pathogenesis and treatment of inflammatory diseases [J].
Dinarello, Charles A. .
BLOOD, 2011, 117 (14) :3720-3732
[10]   Type 2 diabetes as an inflammatory disease [J].
Donath, Marc Y. ;
Shoelson, Steven E. .
NATURE REVIEWS IMMUNOLOGY, 2011, 11 (02) :98-107